| 영문 | Gram stain | 한글 | 그람염색 |
|---|---|---|---|
| 설명 | 미생물을 염색하는 방법 중의 하나. 1884년 덴마크의 의사 H.C.J. 그람(1853~ 1938)이 고안한 특수 염색법이다. 이 염색법을 사용하면 미생물은 양성균과 음성균의 2무리로 크게 나뉜다. 염색법은 균을 유리면에 바르고 가열 고정한다. 젠시안바이오렛, 크리스탈 바이오렛, 메틸바이오렛 등 파라로즈 아닐린계 색소의 어느 하나를 사용하여 우선 염색하고 이어서 루골액을 작용시킨 뒤, 에탄올 또는 아세톤으로 탈색한다. 이때 탈색되지 않고 보라색을 타나내는 것을 그람양성균이라 부르며, 포도알균-폐렴알균-사슬알균 등이 대표적인 예이다. 탈색되면 그람음성균이라 부르며, 대장균-녹농균 등이 있다. 최후에 사프라닌, 푹신 등 적색계의 색소액으로 후염색을 한다. 미생물의 감별에 중요한 염색법이며 염색성의 차이는 영양요구성, 화학요법제(항생물질 등)에 대한 감수성의 차이와도 관련되는 점이 많으므로 사용약제의 선택시에도 중요한 역할을 한다. 그람양성균과 음성균의 차이는 세균벽의 구조에 있는데, 양성균은 세포막의 바깥쪽 펩티드글리칸이라는 당단백질층의 두께가 20~80nm나 되고, 그램음성균의 펩티드글리칸 층은 2~3nm로 얇고, 다시 바깥쪽에 외막이라 부르는 층이 있다. |
||
| DOPA, dopa | dihydroxyphenylalanine |
|---|---|
| L-DOPA, | L-dopa levodopa, levo-3, 4-dihydroxyphenylalanine |
| AFB Stain | Acid Fast Bacilli Stain |
| HE stain | Hematoxylin-Eosin stain |
| WS | Waardenburg syndrome; ward secretary; Warkany syndrome; Warthin-Starry [stain]; water soluble; water... |
| (18)F-DOPA | 6-[(18)F]fluoro-L-DOPA |
|---|---|
| PWS | Port Wine Stain |
| L-DOPA | L-Dihydroxphenylalanine |
| 6-FD | 18F]6-fluoro-L-dopa |
| DOPA | 3,4-dihydrophenylalanine |
| alpha methyl dopa | <drug> An antihypertensive drug, preferred in pregnant patients. (18 Nov 1997) |
|---|---|
| decarboxylated dopa | <drug> A catecholamine neurotransmitter and hormone (153 D), formed by decarboxylation of dehydroxyphenylalanine (dopa). A precursor of adrenaline and noradrenaline. Pharmacologic action: 1. Precursor of norepinephrine 2. Stimulates dopaminergic, alpha and beta-1 adrenergic receptors: 3. Dopaminergic (1-2 mcg/kg per min): cerebral, renal, and mesenteric vasodilation increase urine output 4. Mixed alpha and beta-1 (2-10 mcg/kg per min): increases cardiac ouput with moderate increase systemic vascular resistance 5. Predominantly alpha (>20 mcg/kg per min): increases systemic vascular resistance Uses: 1. Treat hypotension associated with bradycardia 2. Stimulate cardiac output and urine output Dose: 1. Start infusion at 1-5 mcg/kg per min and titrate to effect. 2. Use the lowest dose that provides the desired hemodynamic improvement. 3. Do not exceed 20 mcg/kg per min. Potential complications: 1. May increase pulmonary pressure and worsen pulmonary congestion. 2. May increase myocardial work without improving coronary blood flow, exacerbating myocardial ischemia 3. Stimulates heart rate and may cause supraventricular or ventricular arrhythmias (15 Mar 2000) |
| dopa | An amino acid derived from the amino acid tyrosine. It is formed as the first intermediate in the production of dopamine, a neurotransmitter. (09 Oct 1997) |
| dopa decarboxylase | <enzyme> One of the aromatic-l-amino-acid decarboxylases, this enzyme is responsible for the conversion of dopa to dopamine. It is of clinical importance in the treatment of parkinson's disease. Registry number: EC 4.1.1.- (12 Dec 1998) |
| DOPA dioxygenase | <enzyme> Key enzyme in betalain biosynthesis pathway of amanita muscaria; genbank y12886 Registry number: EC 1.14.99.- Synonym: dopa-4,5-dioxygenase, doda gene product (26 Jun 1999) |
| dopa oxidase | Provisional name given the enzyme(s) catalyzing the formation of melanins from dopa; it now appears that the copper-containing monophenol monooxygenases and/or catechol oxidases are responsible for the oxidation of l-tyrosine to dopa and dopa quinone. (05 Mar 2000) |
| dopa quinone | An oxidation product of dopa and an intermediate in the formation of melanin from tyrosine. (05 Mar 2000) |
| dopa reaction | A dark staining observed in fresh tissue sections to which a solution of dopa has been applied, presumably due to the presence of dopa oxidase in the protoplasm of certain cells. Synonym: Bloch's reaction. (05 Mar 2000) |
| dopa-responsive dystonia | A condition successfully treated with drugs. Typically, DRD begins in childhood or adolescence with progressive difficulty in walking and, in some cases, spasticity. Segawa's dystonia is an important variant of DRD. In Segawa's dystonia, the symptoms fluctuate during the day from relative mobility in the morning to increasingly worse disability in the afternoon and evening as well as after exercise. Some scientists feel DRD is not only rare but also rarely diagnosed since it mimics many of the symptoms of cerebral palsy. (12 Dec 1998) |
| Dopa-tyrosine sulfotransferase | <enzyme> Active towards tyrosine and dopa isomers except dl-ortho-tyrosine; isolated from rat liver; genbank u38419 Registry number: EC 2.8.2.- (26 Jun 1999) |
| dystonia, dopa-responsive | A condition successfully treated with drugs. Typically, DRD begins in childhood or adolescence with progressive difficulty in walking and, in some cases, spasticity. Segawa's dystonia is an important variant of DRD. In Segawa's dystonia, the symptoms fluctuate during the day from relative mobility in the morning to increasingly worse disability in the afternoon and evening as well as after exercise. Some scientists feel DRD is not only rare but also rarely diagnosed since it mimics many of the symptoms of cerebral palsy. (12 Dec 1998) |
| l-dopa | <chemical> The naturally occurring form of dopa and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonism and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. Pharmacological action: antiparkinson agents, dopamine agents. (12 Dec 1998) |
| L-dopa peroxidase | <enzyme> Found in human erythrocytes associated with catalase Registry number: EC 1.11.- (26 Jun 1999) |
| Abbott's stain | <technique> Spores are stained blue with alkaline methylene blue; bodies of the bacilli become pink with eosin counterstain. (05 Mar 2000) |
| aceto-orcein stain | <technique> A stain used for chromosomes in air-dried or squashed cytologic material. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|